NandagopalVrindavanamMD

Oncology • Austin, TX

Physician

Join to view full profile

Dr. Vrindavanam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Vrindavanam's full profile

Already have an account?

Office
9715 Burnett Road
Bldg 7, Sta 200
Austin, TX 78758
Phone+1 512-505-5500

Fax+1 512-334-2883
Is this information wrong?

Summary

Dr. Nandagopal Vrindavanam is an oncologist in Puyallup, WA and is affiliated with MultiCare Tacoma General Hospital. He received his medical degree from Madurai Medical College and has been in practice 28 years. He is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. He has 9 publications and over 150 citings.

Education & Training

University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
Medical University of South CarolinaResidency, Internal Medicine, 1998 - 2000
Madurai Medical CollegeClass of 1989

Certifications & Licensure

FL State Medical License 2015 - 2026
WA State Medical License 2021 - 2025
OH State Medical License 2001 - 2025
TX State Medical License 2016 - 2025
SC State Medical License 1999 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2, Phase 3
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects Start of enrollment: 2011 Jul 01
Terminated
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Start of enrollment: 2014 Jul 14
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Peter A. Kaufman, Hans Wildiers, Gilles Freyer, Margaret Kemeny, Anthony Gonçalves, Guy Jerusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanay...> ;Clinical Breast Cancer. 2019 Feb 1
40 citations
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treat...
M. Catherine Pietanza, Thomas J. Lynch, Primo N. Lara, John Cho, Ronald H. Yanagihara, Nandagopal Vrindavanam, Naveed Chowhan, Shirish M. Gadgeel, Nathan A. Pennell, R...> ;Journal of Thoracic Oncology. 2012 Jan 1
6 citations
Dramatic response to single-agent rituximab in a patient with intravascular lymphoma.
Nandagopal Vrindavanam, Mehdi Hamadani, Barbara Steele, Farrukh T. Awan, Saul Suster, Don M. Benson> ;American Journal of Hematology. 2007 Dec 1
3 citations
Fenfluramine challenge in anxious children.
Floyd R. Sallee, Nandagopal S. Vrindavanam, Hong Liu, Gopalan Sethuraman, Lauren Sine> ;Human Psychopharmacology. 2000 Dec 1
17 citations
Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response
Floyd R. Sallee, Nandagopal S. Vrindavanam, Deborah Deas-Nesmith, April M. Odom, Stanley W. Carson, Gopalan Sethuraman> ;Biological Psychiatry. 1998 Oct 1
40 citations
Expression of β-galactosidase in mouse brain: Utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery system
Sanja Altman-Hamamdzic, Chad H. Groseclose, J.X. Ma, Hamamdzic D, Nandagopal S. Vrindavanam, Lawrence D. Middaugh, N.P. Parratto, Floyd R. Sallee> ;Gene Therapy. 1997 Aug 1
50 citations
Pulse Intravenous Clomipramine for Depressed Adolescents: Double-Blind, Controlled Trial
Floyd R. Sallee, Nandagopal S. Vrindavanam, Deborah Deas-Nesmith, Stanley W. Carson, Gopalan Sethuraman> ;The American Journal of Psychiatry. 1997 May 1
18 citations
Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome
Floyd R. Sallee, Douglas Dougherty, Gopalan Sethuraman, Nandagopal S. Vrindavanam> ;Biological Psychiatry. 1996 Nov 15
16 citations
The effects of phosphorylation on the functional regulation of an expressed recombinant human dopamine transporter
Nandagopal S. Vrindavanam, P. Arnaud, J.X. Ma, Sanja Altman-Hamamdzic, N.P. Parratto, Floyd R. Sallee> ;Neuroscience Letters. 1996 Sep 27
Join now to see all